3.30
                                            Schlusskurs vom Vortag:
              $3.39
            Offen:
              $3.43
            24-Stunden-Volumen:
                52,493
            Relative Volume:
              0.29
            Marktkapitalisierung:
                $10.53M
            Einnahmen:
              -
            Nettoeinkommen (Verlust:
              $-37.75M
            KGV:
              -1.0154
            EPS:
                -3.25
            Netto-Cashflow:
                $-30.91M
            1W Leistung:
              -8.08%
            1M Leistung:
              -42.91%
            6M Leistung:
                +1,119%
            1J Leistung:
              +62.56%
            Cellectar Biosciences Inc Stock (CLRB) Company Profile
Firmenname
                  
                      Cellectar Biosciences Inc
                    
                Sektor
                  Branche
                  Telefon
                  
                      (608) 441-8120
                    
                Adresse
                  
                      100 CAMPUS DRIVE, FLORHAM PARK, NJ
                    
                Vergleichen Sie CLRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                CLRB
                            
                             
                        Cellectar Biosciences Inc 
                           | 
                    3.30 | 10.82M | 0 | -37.75M | -30.91M | -3.25 | 
| 
                         
                          
                                VRTX
                            
                             
                        Vertex Pharmaceuticals Inc 
                           | 
                    426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 | 
| 
                         
                          
                                REGN
                            
                             
                        Regeneron Pharmaceuticals Inc 
                           | 
                    642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 | 
| 
                         
                          
                                ALNY
                            
                             
                        Alnylam Pharmaceuticals Inc 
                           | 
                    434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 | 
| 
                         
                          
                                ARGX
                            
                             
                        Argen X Se Adr 
                           | 
                    826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 | 
| 
                         
                          
                                INSM
                            
                             
                        Insmed Inc 
                           | 
                    186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 | 
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2024-12-05 | Fortgesetzt | Ladenburg Thalmann | Buy | 
| 2020-07-01 | Eingeleitet | Oppenheimer | Outperform | 
| 2020-01-21 | Fortgesetzt | ROTH Capital | Buy | 
| 2019-09-13 | Eingeleitet | ROTH Capital | Buy | 
| 2016-12-21 | Eingeleitet | Ladenburg Thalmann | Buy | 
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Can Cellectar Biosciences Inc. stock surprise with earnings upside2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
Why Cellectar Biosciences Inc. stock could outperform in 2025Layoff News & Smart Allocation Stock Reports - newser.com
Developing predictive dashboards with Cellectar Biosciences Inc. dataJuly 2025 Outlook & Technical Pattern Alert System - newser.com
Will Cellectar Biosciences Inc. bounce back from current supportJuly 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Is Cellectar Biosciences Inc. stock a top pick in earnings seasonAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Will Cellectar Biosciences Inc. (NV4) stock deliver compounding returnsLong Setup & Risk Controlled Swing Alerts - newser.com
Can Cellectar Biosciences Inc. stock hit record highs again2025 Key Highlights & AI Enhanced Trading Signals - newser.com
How strong is Cellectar Biosciences Inc. (NV4) stock earnings growthJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Using R and stats models for Cellectar Biosciences Inc. forecastingPortfolio Update Report & Technical Confirmation Alerts - newser.com
Is now a turning point for Cellectar Biosciences Inc.2025 Market WrapUp & Safe Capital Growth Tips - newser.com
How analysts rate Cellectar Biosciences Inc. stock today2025 Retail Activity & Real-Time Volume Analysis - newser.com
What the charts say about Cellectar Biosciences Inc. today2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
Will Cellectar Biosciences Inc. stock pay special dividendsJuly 2025 Fed Impact & Fast Gain Swing Trade Alerts - newser.com
Will Cellectar Biosciences Inc. benefit from macro trendsTrade Risk Assessment & Low Drawdown Investment Ideas - newser.com
Published on: 2025-11-03 03:03:40 - newser.com
How hedge fund analytics apply to Cellectar Biosciences Inc. stockQuarterly Portfolio Report & Expert Curated Trade Setups - newser.com
Using data filters to optimize entry into Cellectar Biosciences Inc.Portfolio Risk Report & AI Driven Stock Movement Reports - newser.com
Using RSI to spot recovery in Cellectar Biosciences Inc.Chart Signals & Weekly High Return Stock Opportunities - newser.com
Will Cellectar Biosciences Inc. stock gain from government policies2025 Valuation Update & AI Powered Market Trend Analysis - newser.com
Can Cellectar Biosciences Inc. stock deliver sustainable ROEJuly 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Using data tools to time your Cellectar Biosciences Inc. exitJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Is Cellectar Biosciences Inc. stock a safe investment in uncertain markets2025 Price Action Summary & Free Technical Pattern Based Buy Signals - newser.com
Is Cellectar Biosciences Inc. stock a buy in volatile marketsJuly 2025 Spike Watch & Long-Term Safe Return Strategies - newser.com
How Cellectar Biosciences Inc. (NV4) stock correlates with oil marketsWeekly Profit Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Morguard Real Estate Investment Trust T0L a good long term investmentBlue Chip Stock Analysis & Free Long-Term Investment Planning - earlytimes.in
Cellectar Biosciences Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Small Capital Growth Tips - earlytimes.in
Can Cellectar Biosciences Inc. hit a new high this month2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
Why analysts remain bullish on Cellectar Biosciences Inc. stock2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Can Cellectar Biosciences Inc. stock weather global recessionGap Up & Fast Entry Momentum Trade Alerts - newser.com
Has Cellectar Biosciences Inc. found a price floor2025 Market WrapUp & Low Drawdown Investment Ideas - newser.com
Using Python tools to backtest Cellectar Biosciences Inc. strategiesQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Cellectar Biosciences, Inc. (CLRB) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Published on: 2025-11-01 12:28:59 - newser.com
Published on: 2025-11-01 05:42:39 - newser.com
Is Cellectar Biosciences Inc. (NV4) stock supported by strong fundamentalsAnalyst Downgrade & Stock Portfolio Risk Control - newser.com
Finanzdaten der Cellectar Biosciences Inc-Aktie (CLRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):